Last reviewed · How we verify
LY2157299
At a glance
| Generic name | LY2157299 |
|---|---|
| Also known as | TGF-β receptor inhibitor, Galunisertib |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling (PHASE2, PHASE3)
- Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer (PHASE2)
- A Study in Recurrent Glioblastoma (GB) (PHASE2)
- ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer (PHASE2)
- A Dose-Escalation Study in Participants With Recurrent Malignant Glioma (PHASE1)
- Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary (PHASE1)
- Galunisertib Combined With Capecitabine in Advanced CRC With PM (PHASE1, PHASE2)
- Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2157299 CI brief — competitive landscape report
- LY2157299 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI